NICE issues PTNS guidance for overactive bladder

Uroplasty, Inc. (Nasdaq: UPI), announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued a guidance document titled "Percutaneous Posterior Tibial Nerve Stimulation for Overactive Bladder Syndrome," reinforcing the safety and effectiveness of PTNS for overactive bladder.

"The significance of this guidance in the U.K. is a positive statement affirming the evidence that PTNS is efficacious in reducing the symptoms of overactive bladder and there are no major safety concerns," said David Kaysen, President and CEO of Uroplasty. "We will help medical directors of U.S. private payers and Medicare carriers understand this guidance and its significance as we continue to meet with them to expand coverage for our Urgent® PC Neuromodulation System in the United States."

In the U.K., NICE makes recommendations to the country's National Health Service (NHS) on new and existing medicines, treatments and procedures with the goal of improving health and treating and preventing poor health. A copy of the NICE guidance may be found at www.nice.org.uk.